Published in final edited form as:

Atherosclerosis. 2012 December ; 225(2): 408–411. doi:10.1016/j.atherosclerosis.2012.09.035.

Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV Study

Christina M Parrinello, MPH¹, Alan L Landay, PhD², Howard N Hodis, MD³, Stephen J. Gange, PhD⁴, Philip J Norris, MD⁵, Mary Young, MD⁶, Kathryn Anastos, MD¹, Phyllis C Tien, MD^{7,8}, Xiaonan Xue, PhD¹, Jason Lazar, MD, MPH⁹, Lorie Benning, MS⁴, Russell P Tracy, PhD¹⁰, and Robert C Kaplan, PhD¹

¹Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, US

²Department of Immunology/Microbiology, Rush University Medical Center, Chicago, IL, US

³Atherosclerosis Research Unit, University of Southern California, Los Angeles, CA, US

⁴Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

⁵Blood Systems Research Institute, University of California, San Francisco, Departments of Laboratory Medicine and Medicine, San Francisco, CA, US

⁶Department of Medicine, Georgetown University Medical Center, Washington, DC, US

⁷Department of Medicine, University of California, San Francisco, San Francisco, CA, US

⁸San Francisco Veterans Affairs Medical Center, San Francisco, CA, US

⁹Department of Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY, US

¹⁰Departments of Pathology and Biochemistry, University of Vermont College of Medicine, Burlington, VT, US

Abstract

Objective—We examined serum lipids in association with carotid artery intima-media thickness (CIMT) in HIV-infected and HIV-uninfected women.

Methods—In 2003–4, among 1827 Women's Interagency HIV Study participants, we measured CIMT and lipids (high-density lipoprotein cholesterol [HDL-c], low-density lipoprotein cholesterol [LDL-c], total cholesterol [TC], non-HDL-c). A subset of 520 treated HIV-infected women had pre-1997 lipid measures. We used multivariable linear regression to examine associations between lipids and CIMT.

© 2012 Elsevier Ireland Ltd. All rights reserved.

Correspondence: Robert Kaplan, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Belfer 1306C, Bronx NY 10461, 718-430-4076 (p), 718-430-3588 (f), Robert.kaplan@einstein.yu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Results—In HIV-uninfected women, higher TC, LDL-c and non-HDL-c were associated with increased CIMT. Among HIV-infected women, associations of lipids with CIMT were observed in treated but not untreated women. Among the HIV-infected women treated in 2003–4, CIMT was associated both with lipids measured a decade earlier in infection, and with late lipid measurements.

Conclusion—Among HIV-infected women, hyperlipidemia is most strongly associated with subclinical atherosclerosis in treated women. Among treated women, the association appeared strongest early in the disease course.

Keywords

cardiovascular diseases; carotid arteries; HAART; HIV; lipids

Introduction

The advent of antiretroviral therapy (ART) has increased the life expectancy of persons infected with HIV. Increased duration of exposure to HIV, as well as to ART, has prompted the question of whether patients with HIV have an increased risk of cardiovascular disease (CVD). HIV infection results in dyslipidemia, which presents as low HDL-cholesterol (HDL-c), LDL-cholesterol (LDL-c), total cholesterol (TC), and high triglyceride (TG) levels, and may be associated with increased CVD risk [1–4]. Initiation of highly active antiretroviral therapy (HAART) in HIV-infected persons has been shown to increase HDL-c, LDL-c and TC compared to pre-treatment levels [2, 5–8]. Dyslipidemia associated with HAART has also been linked to increased CVD risk and decreased life expectancy [6]. Prior studies have reported varying associations between lipids and subclinical atherosclerosis in HIV-infected and HIV-uninfected populations [9–13].

In this study, we examined the association of serum lipid levels with subclinical atherosclerosis, measured as carotid artery intima-media thickness (CIMT), in HIV-infected and HIV-uninfected women. Among HIV-infected women who were treated at the time of the CIMT, we also examined the ability of lipids measured about 10 years earlier, when most women were untreated, to predict subclinical atherosclerosis.

Methods

We studied 1827 women (1305 HIV-infected and 522 HIV-uninfected) who were enrolled in WIHS during 2 waves of recruitment (1994–1995 and 2001–2002). All women had CIMT and lipids measured approximately concurrently during 2004–2005. Among those women enrolled during 1994–1995, there were 520 HIV-infected women who had blood specimens from the early period of study participation (1994–1997), and who were ART-treated (mostly HAART) at the 2004–2005 visit when CIMT was measured. In the early period of study participation, less than 1% of participants received HAART, 10% received combination therapy, and 31% received monotherapy.

As previously described, standardized B-mode carotid artery ultrasound images were acquired with superimposed simultaneous electrographic tracing and CIMT was centrally measured with in-house developed automated computerized edge detection software (Patents, 2005, 2006, 2011) [14]. Quality control procedures included centralized training of sonographers and repeat imaging and CIMT measurements obtained on the same individual separated by several weeks conducted throughout the study; this yielded a coefficient of variation of 1.8% and an intraclass correlation coefficient of 0.98. All sites performed periodic calibration using a phantom (Gammex, Middleton WI) to assure consistency of images over time and to harmonize measurements collected using different instrumentation.

TC and HDL-c were measured at the early study visits and concurrent with CIMT, while LDL-c was only available for the visits concurrent with CIMT. Non-HDL-c was calculated by subtracting HDL-c from TC. If direct LDL-c was unavailable, we used calculated LDL-c, only if the participant was fasting and had TG levels of 400mg/dL or below. Of the 1827 participants included in the study, 84% (N=440) of HIV-uninfected women and 85% (N=1105) of HIV-infected women were fasting at the visit concurrent with CIMT. Fasting status was not available for the early visits. Treatment was defined as use of HAART, combination therapy or monotherapy at the time of the lipid measurement concurrent with CIMT.

We used multivariable linear regression to examine whether HDL-c, LDL-c, TC and non-HDL-c were associated with concurrent CIMT. Models were run separately in HIV-infected and HIV-uninfected women. Among the HIV-infected women, we further stratified analyses by treatment status (treated versus untreated). Then, among only the treated HIV-infected women who had both early and concurrent lipid measurements, we ran separate models for lipid levels obtained during the early years of study participation and those measured concurrently with CIMT. All models were adjusted for age at time of cholesterol measure and race/ethnicity. Models were further adjusted for smoking status and BMI (and CD4+ T cell count and log-transformed HIV RNA in HIV-infected women), to control for potential confounding. Fewer than 6% of women reported lipid-lowering medication, so we did not adjust for this. Analyses were performed using SAS software (version 9.2, SAS Systems, Cary, NC).

Results

Characteristics of HIV-infected and HIV-uninfected women

The majority of study participants were Black/African-American and nearly half were current smokers (Table 1). Mean age was between 38.0 and 42.2 years in HIV-uninfected, untreated HIV-infected, and treated HIV-infected groups ($P<0.0001$, Table 1). Compared to untreated HIV-infected women, treated HIV-infected women had higher levels of HDL-c, LDL-c, TC and non-HDL-c (all $P<0.0001$, Table 1). Compared to HIV-uninfected women, treated HIV-infected women had higher levels of TC and non-HDL-c ($P=0.03$ and $P<0.0001$, respectively) and lower HDL-c levels ($P<0.0001$, Table 1).

Association of lipid values and CIMT measured concurrently

Adjusted for age and race/ethnicity, among 522 HIV-uninfected women, higher TC, LDL-c and non-HDL-c levels were statistically significantly associated with higher CIMT (Table 2). Adjusted for age and race/ethnicity, among 836 HIV-infected women receiving ART, higher LDL-c level was significantly associated with higher CIMT, higher non-HDL-c level had a borderline significant association with higher CIMT, and TC level had no significant association with CIMT (Table 2). After adjustment for BMI and smoking, in HIV-uninfected women these significant associations persisted at $P<0.05$, but in treated HIV-infected women the associations between lipids and CIMT became non-significant ($P=0.14$ for LDL-c and $P=0.20$ for non-HDL-c) (data not shown). Among 469 untreated HIV-infected women, we did not find a significant association of lipid measures with CIMT (Table 2). HDL-c levels were not associated with CIMT in either HIV-infected or HIV-uninfected groups.

Lipids measured during pre-HAART and post-HAART era

Among 520 of the 836 antiretroviral-treated HIV-infected women, lipid levels had been measured both during the pre-HAART era and at the time of CIMT (2003–2004). Mean age was 36 years at the time of the pre-HAART lipid measurements and 46 years at the time of

CIMT. Among these women, 41% received any HIV treatment (mainly monotherapy) at the time of early lipid measurement (Table 1). Among these women, at pre-HAART visits higher TC level was significantly associated with higher CIMT (adjusted for age and race/ethnicity, difference in CIMT per 10 mg/dL increment in TC = 3.39 μ m, 95% CI 0.57 to 6.22, $P=0.02$). At visits during the HAART era, the difference in CIMT per 10 mg/dL increment in TC level was 2.01 μ m (95% CI -0.17 to 4.19, $P=0.07$). There was a significant association between non-HDL-c level and CIMT at pre-HAART visits (difference in CIMT per 10 mg/dL non-HDL-c increment = 3.44 μ m, 95% CI 0.34 to 6.54, $P=0.03$) and a nonsignificant trend suggesting an association between non-HDL-c and CIMT during the HAART era (difference in CIMT per 10 mg/dL non-HDL-c increment = 2.08 μ m, 95% CI = -0.16 to 4.32, $P=0.07$). HDL-c level measured either in the pre-HAART or HAART era had no association with CIMT (data not shown).

Discussion

As is well-known, among HIV-uninfected women higher levels of TC, LDL-c and non-HDL-c are risk factors for atherosclerosis, which we confirmed in our data using CIMT as a measure of subclinical atherosclerosis. Among HIV-infected women, we made several important observations about lipids and CIMT. First, in untreated HIV-infected women, we did not find a significant association between lipid levels and concurrent CIMT; the point estimates actually suggested less rather than more atherosclerosis in women with higher lipid levels. Second, among treated HIV-infected women, higher levels of LDL-c and non-HDL-c were associated with higher CIMT. These associations appeared weaker than those observed in the HIV-uninfected women. TC levels were also significantly associated with CIMT only in the HIV-uninfected group. Third, among a group of treated HIV-infected women who had lipid measurements both early and late in follow-up, lipids at both time points were associated with CIMT, with somewhat stronger and more statistically significant associations in the early era. Finally, in all analyses of HIV-infected and HIV-uninfected groups, HDL-c level was not associated with CIMT.

Our findings, along with results from previous studies [3, 6, 10–13], raise questions about what may be an evolving relationship between lipid abnormalities and atherosclerosis across the course of HIV infection. An important study limitation is lack of information about duration of HIV infection. Therefore, we can only make indirect inference about what may have distinguished the disease stages of the HIV-infected women who remained untreated during 2003–2004, the HIV-infected women who were treated in 2003–2004, and the latter group of women when studied ten years earlier. However, among HIV-infected women, we showed that hyperlipidemia has the strongest association with atherosclerosis in women on treatment. Similarly, inflammatory and hemostasis markers (including soluble IL-2 receptor, interleukin-6 and D-dimer) are more strongly associated with CIMT when measured while on HAART, as compared with the period shortly prior to HAART initiation [15]. This leads us to hypothesize that the associations between lipid measures and CIMT may be modified or dependent upon inflammatory or immune activation processes, which evolve over the course of HIV infection. From a clinical perspective, physicians should recognize that the ability of lipids to predict CVD risk may be weaker in HIV-infected women than in HIV-uninfected women, that predictive ability of lipids may differ across subgroups of the HIV-infected population, and that among women who are untreated relatively late in infection, lipids may be of limited value in identifying patients who are at increased risk of CVD.

Acknowledgments

Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY

(Howard Minkoff); Washington, DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590) and by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (U01-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Additional co-funding is provided by the National Heart, Lung and Blood Institute (1R01HL095140, 1R01HL083760 to R.C.K.). Partial funding for laboratory and imaging work as well as assistance with general study coordination was provided by the University of Washington's CVD and Metabolic Complications of HIV/AIDS Data Coordinating Center (5R01HL095126).

The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

References

1. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. *Atherosclerosis*. 2008; 199:79–86. [PubMed: 18054941]
2. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. *J Acquir Immune Defic Syndr*. 2007; 45:34–42. [PubMed: 17460470]
3. Asztalos BF, Schaefer EJ, Horvath KV, et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. *Atherosclerosis*. 2006; 184:72–77. [PubMed: 15935358]
4. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. *JAMA*. 2003; 289:2978–2982. [PubMed: 12799406]
5. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. *Antivir Ther*. 2005; 10:585–591. [PubMed: 16152752]
6. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. *The American journal of cardiology*. 2005; 95:586–591. [PubMed: 15721096]
7. Almeida SE, Borges M, Fiegenbaum M, Nunes CC, Rossetti ML. Metabolic changes associated with antiretroviral therapy in HIV-positive patients. *Rev Saude Publica*. 2009; 43:283–290. [PubMed: 19225696]
8. Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. *HIV Med*. 2007; 8:280–287. [PubMed: 17561873]
9. Herder M, Johnsen SH, Arntzen KA, Mathiesen EB. Risk Factors for Progression of Carotid Intima-Media Thickness and Total Plaque Area: A 13-Year Follow-Up Study: The Tromso Study. *Stroke*. 2012; 43:1818–1823. [PubMed: 22550052]
10. Kwiatkowska W, Knysz B, Drelichowska-Durawa J, et al. Subclinical carotid atherosclerosis and cardiovascular risk factors in HIV-infected patients. *Postepy Hig Med Dosw (Online)*. 2011; 65:770–783. [PubMed: 22173442]
11. Badiou S, Thiebaut R, Aurillac-Lavignolle V, et al. Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients. *J Infect*. 2008; 57:47–54. [PubMed: 18554723]
12. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. *AIDS*. 2008; 22:1615–1624. [PubMed: 18670221]
13. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. *Circulation*. 2004; 109:1603–1608. [PubMed: 15023877]
14. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 2001; 135:939–953. [PubMed: 11730394]
15. Kaplan RC, Landay AL, Hodis HN, et al. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. *J Acquir Immune Defic Syndr*. 2012; 60:359–368. [PubMed: 22592585]

Table 1

Characteristics of study populations

	Women with lipids measured only in 2004–2005				Women with lipids measured in both 1994–1997 and 2004–2005	
	HIV-uninfected (N=522)		HIV-infected, untreated (N=469)		HIV-infected, treated (N=520)	
	Mean (SD) or N (%)	Mean (SD) or N (%)	Mean (SD) or N (%)	Mean (SD) or N (%)	Mean (SD) or N (%)	Mean (SD) or N (%)
HDL-c, mg/dL	54.4 (16.6)	41.7 (16.2)	50.0 (17.8)	46.5 (12.2)	50.0 (18.3)	
LDL-c, mg/dL	105.0 (34.7)	94.4 (32.5)	103.1 (33.5)	N/A	102.5 (34.1)	
TC, mg/dL	176.6 (40.1)	161.9 (40.5)	181.7 (42.5)	165.7 (34.2)	182.6 (43.9)	
Non-HDL-c, mg/dL	122.2 (41.3)	120.7 (37.7)	132.1 (41.3)	119.2 (31.0)	133.3 (42.8)	
Age, years	38.0 (10.1)	40.4 (8.9)	42.2 (8.6)	36.0 (7.8)	45.5 (7.8)	
CIMT, μm	720.3 (120.7)	720.0 (110.5)	727.9 (116.7)	N/A	749.6 (121.0)	
Race/Ethnicity						
African-American/Black	320 (61%)	308 (66%)	447 (53%)	282 (54%)	Same	
Hispanic	145 (28%)	120 (25%)	258 (31%)	136 (26%)	Same	
White/Other	57 (11%)	41 (9%)	131 (16%)	102 (20%)	Same	
Current smoking	258 (50%)	241 (52%)	334 (40%)	256 (49%)	222 (43%)	
BMI, kg/m²	30.8 (8.4)	29.0 (8.9)	27.9 (7.0)	27.2 (6.4)	27.7 (6.9)	
Current CD4+ T cell count, cells/μL[*]	N/A	377 (240–567)	462 (279–661)	346 (224–490)	435 (259–653)	
HIV RNA, log₁₀ copies/mL	N/A	3.7 (1.1)	2.5 (1.0)	4.2 (0.9)	2.5 (1.0)	
Treatment at visit						
PI-HAART	N/A	N/A	413 (49%)	1 (0%)	276 (53%)	
NNRTI-HAART	N/A	N/A	259 (31%)	2 (0%)	141 (27%)	
Other HAART	N/A	N/A	136 (16%) ^{**}	0 (0%)	80 (15%) ^{***}	
Combination Therapy	N/A	N/A	24 (3%)	54 (10%)	20 (4%)	
Monotherapy	N/A	N/A	4 (1%)	161 (31%)	3 (1%)	

* Presented as median and interquartile range

49 women were on a HAART regimen containing both a PI and NNRTI; 87 women were on a HAART regimen containing neither a PI nor an NNRTI
 ***
 35 women were on a HAART regimen containing both a PI and NNRTI; 45 women were on a HAART regimen containing neither a PI nor an NNRTI
 ***

Table 2

Associations of HDL-c, LDL-c, TC and non-HDL-c with carotid artery intima-media thickness in the study populations

	HIV-uninfected women (N=522)			Untreated HIV-infected women (N=469)			ARV-treated HIV-infected women (N=836)		
	Difference in CIMT (μm)	95% CI	P value	Difference in CIMT (μm)	95% CI	P value	Difference in CIMT (μm)	95% CI	P value
HDL-c	-1.06	(-3.59,1.47)	0.41	-0.71	(-3.29,1.87)	0.59	-0.82	(-2.79,1.16)	0.42
TC	2.17	(0.07,4.27)	0.04	-1.00	(-3.07,1.07)	0.34	1.32	(-0.32,2.96)	0.11
LDL-c	3.46	(1.02,5.90)	0.01	-0.52	(-3.08,2.04)	0.69	2.27	(0.19,4.35)	0.03
Non-HDL-c	2.40	(0.36,4.44)	0.02	-0.61	(-2.80,1.58)	0.58	1.66	(-0.03,3.36)	0.05

Models adjusted for age and race/ethnicity

Results presented per 5 mg/dL increase in HDL-c, and 10 mg/dL increase in TC, LDL-c and non-HDL-c